Steatotic liver disease (commonly called fatty liver disease) progresses silently. Even in the absence of noticeable symptoms ...

The study builds on recent USC research showing that, for adolescents undergoing bariatric surgery to manage obesity, a PFAS ...

Chronic liver disease (CLD) is responsible for significant morbidity and mortality. Most liver-related outcomes occur in people with advanced CLD, yet liver disease can be asymptomatic until the late ...

Familial Hypobetalipoproteinemia (FHBL), caused by variants in the apolipoprotein B (APOB) gene, is a rare autosomal ...

NASH kNOWledge redesigns website; introduces new URL as 6-year anniversary approaches PITTSBURGH, PA / ACCESSWIRE / August 27, 2024 / NASH kNOWledge today announces a refreshed website and new URL to ...

This Collection supports and amplifies research related to SDG 3. Gastrointestinal and liver cancers are one of the leading causes of mortality, with incidence on the rise globally for several cancers ...

Myosteatosis, the pathological infiltration of fat into skeletal muscle, is increasingly recognized as a key predictor of ...

New research calls for routine risk stratification of MASLD in people with obesity to detect and manage liver disease earlier ...

WALTHAM, Mass., Feb. 26, 2024 /PRNewswire/ -- More than 100 million people in the U.S. are affected by some form of liver disease, but only 4.5 million adults have been diagnosed with the condition.

New analysis shows alcohol-related liver disease remains a major cause of cirrhosis and liver death. Read more.

On Thursday, the Food and Drug Administration announced its approval of the first ever therapeutic treatment targeting metabolic dysfunction-associated steatohepatitis (MASH). This represents a ...